Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

To be included in this study, participants must:

- Sign a consent form;

- Be older 18 or older and 90 or younger;

- Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a
rectal device;

- Test positive for Clostridium difficile;

- If female, must not be pregnant or nursing and take appropriate measures to not get
pregnant during the study.

Participants will not be allowed into the study if they:

- Have toxic megacolon and/or known small bowel ileus;

- Have received treatment with intravenous immune globulin (IVIG)within the past 30
days;

- Have received treatment with a fecal transplant within 7 days, and/or if the doctor
anticipates to give the participant a fecal transplant during the study;

- Have received a certain amount of antibacterial therapy specific for current CDAD,
unless it is not working;

- Have received an investigational vaccine against C. difficile;

- Have received an investigational product containing monoclonal antibodies against
toxin A or B within 180 days;

- Had more than 2 episodes of CDAD within 90 days;

- Had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3
months(this does not include appendectomy or cholecystectomy);

- Have history of prior inflammatory bowel disease: ulcerative colitis, Crohn's
disease, or microscopic colitis;

- Are unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine
during the duration of the study;

- Are unable to discontinue opiate treatment unless on a stable dose;

- Has known positive stool cultures for other enteropathogens including but not limited
to Salmonella, Shigella, and Campylobacter;

- Had stool studies positive for pathogenic ova and/or parasites;

- Have an intolerance or hypersensitivity to daptomycin and/or vancomycin;

- Have life-threatening illness at the time of enrollment;

- Have poor concurrent medical risks that in the opinion of the Investigator the
participant should not enroll;

- Have received an investigational drug or participated in any experimental procedure
within 1 month;

- Have HIV, a CD4 < 200 cells/mm3 within 6 months of start of study therapy;

- Anticipate that certain antibacterial therapy for a non-CDAD infection will be
required for > 7 days;

- Are unable to discontinue Saccharomyces or similar probiotic;

- Are on a concurrent intensive induction chemotherapy, radiotherapy, or biologic
treatment for active malignancy;

- Are unable to comply with the protocol requirements;

- Have any condition that, in the opinion of the Investigator, might interfere;

- Are not expected to live for less than 8 weeks.